Bronchiolitis Obliterans Syndrome Treatment Market Size in the 7MM was ~USD 58 Million in 2022 and is anticipated to grow with a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bronchiolitis Obliterans Syndrome, historical and forecasted epidemiology as well as the Bronchiolitis Obliterans Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Bronchiolitis Obliterans Syndrome Market with DelveInsight's In-Depth Report @ Bronchiolitis Obliterans Syndrome Market Size- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bronchiolitis Obliterans Syndrome Market Report
• In February 2025:- Deciphera Pharmaceuticals:- The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
• In February 2025:- Byung-Sik Cho:- A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease.
• In February 2025:- Incyte Corporation:- This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
• In February 2025:- Sanofi:-The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.
• In February 2025:- Kadmon, a Sanofi Company:- The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy aged 12 years and above.
• In 2023, there were approximately 34,000 diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome in the 7MM, and this number is expected to rise by 2034.
• In 2023, there were around 34,000 treated cases of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM. According to DelveInsight's analysts, this number is projected to increase by 2034.
• In 2023, the EU4 and the UK had approximately 14,000 diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS), with this number expected to rise by 2034. Within this group, Germany recorded the highest number of diagnosed prevalent BOS cases in 2023.
• In 2023, the United States had the highest number of diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) among the 7MM, with approximately 18,000 cases. This number is expected to increase by 2034.
• According to DelveInsight's analysts, Japan had approximately 1,000 Grade 0 or 0p cases, around 400 Grade 1 (mild) cases, roughly 500 Grade 2 (moderate) cases, and about 400 Grade 3 (severe) cases of Bronchiolitis Obliterans Syndrome (BOS) in 2023. These numbers are expected to rise during the forecast period from 2024 to 2034.
• Bronchiolitis Obliterans Syndrome Companies such as Incyte Corporation, Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing Pharma, Incyte Biosciences, OrphAI Therapeutics, Sanofi, Mallinckrodt, GlaxoSmithKline, Genentech, and others
• Promising Bronchiolitis Obliterans Syndrome Therapies such as JAKAFI (ruxolitinib), ARINA-1, Liposomal Cyclosporine A, itacitinib, TQ05105 tablets, INCA034176, LAM-001, Belumosudil, Extracorporeal Photopheresis (ECP), SERETIDE, ESBRIET (pirfenidone), and others

Stay ahead in the Bronchiolitis Obliterans Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Bronchiolitis Obliterans Syndrome Market Outlook- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiolitis Obliterans Syndrome Epidemiology Segmentation in the 7MM
• Total diagnosed prevalence of Bronchiolitis Obliterans Syndrome
• Grade-specific Bronchiolitis Obliterans Syndrome cases
• Total treated cases of Bronchiolitis Obliterans Syndrome

Download the report to understand which factors are driving Bronchiolitis Obliterans Syndrome epidemiology trends @ Bronchiolitis Obliterans Syndrome Prevalence- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Bronchiolitis Obliterans Syndrome Drugs Profile
• Liposomal Cyclosporine A: Zambon Pharma
Liposomal Cyclosporine A for inhalation (L-CsA-i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L-CsA-i is administered via a drug-specific investigational eFlow technology nebulizer system. The investigational drug-device combination is designed to deliver L-CsA-i to the site of disease in the lung. L-CsA-i is currently being evaluated to treat Bronchiolitis Obliterans Syndrome (BOS) in patients aged 6 years and older in the BOSTON clinical development program, which comprises five ongoing or planned trials. The drug has been awarded Fast Track designation from the US FDA for the treatment of Bronchiolitis Obliterans Syndrome (BOS). As currently, no approved treatment is available for patients with Bronchiolitis Obliterans Syndrome (BOS), a rare, devastating disease that displays a huge unmet medical need. L-CsA-I can potentially address the existing unmet need of Bronchiolitis Obliterans Syndrome (BOS) and fetch maximum revenue.

• MPH966 (alvelestat): Mereo Biopharma
MPH-966 (formerly AZD 9668) is a novel, oral-small molecule that inhibits neutrophil elastase (NE). This neutrophil protease is a key enzyme in destroying lung tissues. Alvelestat is currently being investigated in Phase I/II study in adult patients who have undergone hematopoietic stem cell transplantation and were diagnosed with Bronchiolitis Obliterans Syndrome (BOS). Interim results of Phase I/II clinical study of alvelestat have shown efficacious in the treatment of Bronchiolitis Obliterans Syndrome (BOS). Alvelestat is a disease-modifying agent and can be a blockbuster in treating Bronchiolitis Obliterans Syndrome (BOS).

Bronchiolitis Obliterans Syndrome market Outlook
Bronchiolitis Obliterans Syndrome treatment after lung transplant/allo-HSCT involves augmenting immunosuppression as a form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone are used to treat Bronchiolitis Obliterans Syndrome (BOS) after transplant. Azithromycin has been demonstrated to improve lung function and lower the incidence of Bronchiolitis Obliterans Syndrome (BOS). The reduction in lung function in Bronchiolitis Obliterans Syndrome (BOS) post-HSCT can be slowed down by combining inhaled fluticasone, oral montelukast, and Zithromax.

Get In-Depth Knowledge on Bronchiolitis Obliterans Syndrome Market Trends and Forecasts with DelveInsight @ Bronchiolitis Obliterans Syndrome Treatment Market- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiolitis Obliterans Syndrome Therapies and Companies
• JAKAFI (ruxolitinib): Incyte Corporation
• ARINA-1: Renovion, Inc.
• Liposomal Cyclosporine A: Zambon SpA
• itacitinib: Incyte Corp.
• TQ05105 tablets: Chia Tai Tianqing Pharma
• INCA034176: Incyte Biosciences
• LAM-001: OrphAI Therapeutics
• Belumosudil: Sanofi
• Extracorporeal Photopheresis (ECP): Mallinckrodt
• SERETIDE: GlaxoSmithKline
• ESBRIET (pirfenidone): Genentech

Bronchiolitis Obliterans Syndrome Market Strengths
• Improved understanding of the pathogenesis of BOS in different patient populations has led to studies in identifying potential noninvasive biomarkers for the early diagnosis of BOS
• Different possible disease pathways responsible for BOS progression and loss of lung dysfunction have been studied, helps in identifying new targets for the cure and management of BOS.

Bronchiolitis Obliterans Syndrome Market Opportunities
• Currently, there is only symptomatic treatment available for BOS patients. Both prophylactic treatment therapies and therapies for the cure and management of BOS are yet to be approved.
• A small but increasing patient pool and governmental support to treat BOS allow companies to market new therapies with higher margins.

Unlock Strategic Insights with DelveInsight's Comprehensive Bronchiolitis Obliterans Syndrome Market Report @ Bronchiolitis Obliterans Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bronchiolitis Obliterans Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Bronchiolitis Obliterans Syndrome Companies: Incyte Corporation, Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing Pharma, Incyte Biosciences, OrphAI Therapeutics, Sanofi, Mallinckrodt, GlaxoSmithKline, Genentech, and others
• Bronchiolitis Obliterans Syndrome Therapies: JAKAFI (ruxolitinib), ARINA-1, Liposomal Cyclosporine A, itacitinib, TQ05105 tablets, INCA034176, LAM-001, Belumosudil, Extracorporeal Photopheresis (ECP), SERETIDE, ESBRIET (pirfenidone), and others
• Bronchiolitis Obliterans Syndrome Therapeutic Assessment: Bronchiolitis Obliterans Syndrome current marketed and Bronchiolitis Obliterans Syndrome emerging therapies
• Bronchiolitis Obliterans Syndrome Market Dynamics: Bronchiolitis Obliterans Syndrome market drivers and Bronchiolitis Obliterans Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bronchiolitis Obliterans Syndrome Unmet Needs, KOL's views, Analyst's views, Bronchiolitis Obliterans Syndrome Market Access and Reimbursement

To know more about Bronchiolitis Obliterans Syndrome companies working in the treatment market, visit @ Bronchiolitis Obliterans Syndrome Clinical Trials and Treatments- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Bronchiolitis Obliterans Syndrome Market Report Introduction
2. Executive Summary for Bronchiolitis Obliterans Syndrome
3. SWOT analysis of Bronchiolitis Obliterans Syndrome
4. Bronchiolitis Obliterans Syndrome Patient Share (%) Overview at a Glance
5. Bronchiolitis Obliterans Syndrome Market Overview at a Glance
6. Bronchiolitis Obliterans Syndrome Disease Background and Overview
7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Bronchiolitis Obliterans Syndrome
9. Bronchiolitis Obliterans Syndrome Current Treatment and Medical Practices
10. Bronchiolitis Obliterans Syndrome Unmet Needs
11. Bronchiolitis Obliterans Syndrome Emerging Therapies
12. Bronchiolitis Obliterans Syndrome Market Outlook
13. Country-Wise Bronchiolitis Obliterans Syndrome Market Analysis (2020-2034)
14. Bronchiolitis Obliterans Syndrome Market Access and Reimbursement of Therapies
15. Bronchiolitis Obliterans Syndrome Market Drivers
16. Bronchiolitis Obliterans Syndrome Market Barriers
17. Bronchiolitis Obliterans Syndrome Appendix
18. Bronchiolitis Obliterans Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Ventral hernia market- ttps://www.delveinsight.com/report-store/hernia-repair-devices-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Baricose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Pouchitis market- https://www.delveinsight.com/report-store/pouchitis-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.